AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00978432
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day for Part 1 of the trial
Trial: NCT00978432
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
Trial: NCT00683332
Drug: Tigecycline (Tygacil)
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
Trial: NCT04505397
Drug: SKL24741
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
Trial: NCT04505397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic SKL24741
Trial: NCT01168700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.2 g per day for 12 weeks.
Trial: NCT02752971
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03028350
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with oral placebo daily for 8 weeks
Trial: NCT00084617
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03703570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03776487
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04643457
Drug: UCB9741
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Trial: NCT04643457
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
Trial: NCT04643457
Drug: Subcutaneous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
Trial: NCT00552526
Drug: Antiepileptic drug (AED)
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
Trial: NCT00745199
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
Trial: NCT00151970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
Trial: NCT01364675
Drug: Metformin+Enalapril+Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
Trial: NCT01364675
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical Placebo Tablet
Trial: NCT04562025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
Trial: NCT01315236
Drug: Liposomal amikacin for inhalation (LAI)
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension.
Trial: NCT01315236
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.
Trial: NCT02221622
Drug: Placebo injection (intravenous solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT03191578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo
Trial: NCT02628665
Drug: photosensitizer(photofrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: photosensitizer(photofrin): 2mg/kg
Trial: NCT00926588
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
Trial: NCT02145507
Drug: SOLX (Investigational)
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
Trial: NCT00470184
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01131351
Drug: Optimized Background Regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Trial: NCT03590197
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3 mg/ day with Valproate
Trial: NCT04314531
Drug: matching placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 1 mL injection of placebo
Trial: NCT02079090
Drug: Fentofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
Trial: NCT04296279
Drug: FMP014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Falciparum Malaria Protein-14
Trial: NCT01082640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat placebo-matching capsules
Trial: NCT01143272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01358019
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1, 2, and 3 in a cycle that consists of 21-days
Trial: NCT01251406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Trial: NCT01251406
Drug: rhNRG-1 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Trial: NCT01251406
Drug: rhNRG-1 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Trial: NCT01411670
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment
Trial: NCT00745225
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily, 96 weeks.
Trial: NCT02235259
Drug: XG-104
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
Trial: NCT02235259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02704546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
Trial: NCT01931748
Drug: MELSMON
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02107937
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
Trial: NCT01931748
Drug: UNCNT
RxNorm normalized name: Unspecified Contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01595984
Drug: cyclosporin + mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antirejection drug, renal transplantation
Trial: NCT01595984
Drug: everolimus + mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antirejection drug, renal transplantation
Trial: NCT01809132
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc Sulfate, nutritional supplement
Trial: NCT04111536
Drug: liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
Trial: NCT00108186
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
Trial: NCT01641237
Drug: no added fluoride in a silica base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no added fluoride
Trial: NCT02398448
Drug: Zyloprim® 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04526691
Drug: KEYTRUDA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
Trial: NCT01875003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab matching placebo will be administered as SC injection Q4W.
Trial: NCT01875003
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Trial: NCT01993251
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
Trial: NCT01993251
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
Trial: NCT01993251
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
Trial: NCT01993251
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule, placebo, oral, once a day, 30 minutes before bedtime
Trial: NCT02288143
Drug: COOL-COS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm.
Trial: NCT01231854
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
Trial: NCT01423656
Drug: LEO 29102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01423656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: LEO 29102 vehicle
Trial: NCT00513565
Drug: single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Trial: NCT00678379
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline
Trial: NCT00009061
Drug: GW433908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00644553
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
Trial: NCT00143091
Drug: CP-316,311
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02432313
Drug: Modified Release Formulation x (MRx)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
Trial: NCT01407575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT01062139
Drug: Xarlin (Levocetirizine)
RxNorm normalized name: BLACK MARLIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy compared to mono therapy
Trial: NCT01062139
Drug: Cosalin (Petasites hybridus CO2 extract)
RxNorm normalized name: Cosamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy compared to mono therapy
Trial: NCT00380770
Drug: Generic HAART Triomune : d4T, 3TC, NVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
Trial: NCT00380770
Drug: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
Trial: NCT04536831
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D will be given to group B slected by Lottery method
Trial: NCT04428775
Drug: ALZT-OP1a (cromolyn)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory
Trial: NCT00044551
Drug: Taxane (Cytotoxic, BAY59-8862)
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 1 h infusion every 3 weeks
Trial: NCT01859585
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg intravenous
Trial: NCT01905124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets orally every 12 hours for 24 weeks
Trial: NCT03203499
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally.
Trial: NCT02709590
Drug: diclofenac potassium + lidocaine
RxNorm normalized name: diclofenac / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
Trial: NCT02709590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
Trial: NCT01383096
Drug: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
Trial: NCT00087399
Drug: antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03847207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo Solution
Trial: NCT00752115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab, day 1,8 and 15 in each cycle.
Trial: NCT03862040
Drug: Standard of Care Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care antibiotic treatment for pneumonia
Trial: NCT03660488
Drug: Benzathine Penicillin G
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
Trial: NCT00894465
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children are randomized to receive a placebo prior to undergoing VCUG
Trial: NCT04569032
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Trial: NCT04569032
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Trial: NCT00909181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Trial: NCT00404066
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
Trial: NCT00404066
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
Trial: NCT00298467
Drug: MDX-060
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408330
Drug: Inactive 15% gel base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, topically applied daily for six weeks
Trial: NCT03743883
Drug: Acetylsalicylic Acid(BAYE4465, Aspirin )
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration according to clinical practice
Trial: NCT00844207
Drug: Fixed combination of Azithromycin and Chloroquine
RxNorm normalized name: chloroquine and proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
Trial: NCT00844207
Drug: Azithromycin and Chloroquine
RxNorm normalized name: chloroquine and proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
Trial: NCT01925352
Drug: Ad-HGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.